TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company developing T cell receptor-engineered T cell (TCR-T) therapies for cancer treatment, has announced its participation in two upcoming investor conferences:
1. Morgan Stanley 22nd Annual Global Healthcare Conference: Fireside chat on September 5, 2024, at 8:30 a.m. ET at the New York Marriott Marquis.
2. H.C. Wainwright 26th Annual Global Investment Conference: Presentation on September 10, 2024, at 9:00 a.m. ET at the Lotte New York Palace Hotel.
Webcasts of both events will be available on TScan's website under the "Events and Presentations" section, with archived replays accessible for 90 days post-event.
TScan Therapeutics (Nasdaq: TCRX), azienda biotech in fase clinica che sviluppa terapie T cell receptor-engineered T cell (TCR-T) per il trattamento del cancro, ha annunciato la sua partecipazione a due prossime conferenze per investitori:
1. 22ª Conferenza Annuale sulla Salute Globale di Morgan Stanley: Discussione informale il 5 settembre 2024, alle 8:30 a.m. ET presso il New York Marriott Marquis.
2. 26ª Conferenza Annuale sugli Investimenti Globali di H.C. Wainwright: Presentazione il 10 settembre 2024, alle 9:00 a.m. ET presso il Lotte New York Palace Hotel.
I webcast di entrambi gli eventi saranno disponibili sul sito di TScan nella sezione 'Eventi e Presentazioni', con repliche archiviate accessibili per 90 giorni dopo l'evento.
TScan Therapeutics (Nasdaq: TCRX), una compañía biofarmacéutica en etapa clínica que desarrolla terapias de T células diseñadas por receptores (TCR-T) para el tratamiento del cáncer, ha anunciado su participación en dos próximas conferencias para inversores:
1. 22ª Conferencia Anual de Salud Global de Morgan Stanley: Charla junto a la chimenea el 5 de septiembre de 2024, a las 8:30 a.m. ET en el New York Marriott Marquis.
2. 26ª Conferencia Anual de Inversiones Globales de H.C. Wainwright: Presentación el 10 de septiembre de 2024, a las 9:00 a.m. ET en el Lotte New York Palace Hotel.
Las retransmisiones de ambos eventos estarán disponibles en el sitio web de TScan en la sección 'Eventos y Presentaciones', con repeticiones archivadas accesibles por 90 días después del evento.
TScan Therapeutics (Nasdaq: TCRX)은 암 치료를 위한 T 세포 수용체 조작 T 세포 (TCR-T) 치료법을 개발하는 임상 단계의 생명공학 회사로, 두 개의 다가오는 투자자 회의에 참여한다고 발표했습니다:
1. 모건 스탠리 제22회 글로벌 헬스케어 컨퍼런스: 2024년 9월 5일 오전 8시 30분 ET, 뉴욕 메리어트 마르퀴스에서의 불끄기 채팅.
2. H.C. 웨인라이트 제26회 글로벌 투자 컨퍼런스: 2024년 9월 10일 오전 9시 ET, 롯데 뉴욕 팰리스 호텔에서의 발표.
두 이벤트의 웹캐스트는 TScan 웹사이트의 '이벤트 및 발표' 섹션에서 확인할 수 있으며, 이벤트 종료 후 90일 동안 아카이브된 재생이 가능합니다.
TScan Therapeutics (Nasdaq: TCRX), une société biopharmaceutique en phase clinique développant des thérapies par cellules T à récepteurs d'antigène (TCR-T) pour le traitement du cancer, a annoncé sa participation à deux conférences pour investisseurs à venir :
1. 22ème Conférence Annuelle Mondiale de la Santé de Morgan Stanley : Discussion informelle le 5 septembre 2024 à 8h30 ET au New York Marriott Marquis.
2. 26ème Conférence Annuelle d'Investissement Mondial de H.C. Wainwright : Présentation le 10 septembre 2024 à 9h00 ET au Lotte New York Palace Hotel.
Des retransmissions des deux événements seront disponibles sur le site de TScan dans la section 'Événements et Présentations', avec des rediffusions archivées accessibles pendant 90 jours après l'événement.
TScan Therapeutics (Nasdaq: TCRX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das an T-Zell-Rezeptoren basierte T-Zell (TCR-T) Therapien zur Krebsbehandlung entwickelt, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen bekannt gegeben:
1. 22. Morgan Stanley Global Healthcare Conference: Fireside Chat am 5. September 2024 um 8:30 Uhr ET im New York Marriott Marquis.
2. 26. H.C. Wainwright Global Investment Conference: Präsentation am 10. September 2024 um 9:00 Uhr ET im Lotte New York Palace Hotel.
Webcasts beider Veranstaltungen sind auf der Website von TScan im Abschnitt 'Veranstaltungen und Präsentationen' verfügbar, mit archivierten Wiederholungen, die 90 Tage nach der Veranstaltung zugänglich sind.
- None.
- None.
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced that the Company will participate in the following upcoming investor conferences:
- Morgan Stanley 22nd Annual Global Healthcare Conference; the fireside chat will be held at the New York Marriott Marquis on Thursday, September 5, 2024 at 8:30 a.m. ET
- H.C. Wainwright 26th Annual Global Investment Conference; the presentation will be held at the Lotte New York Palace Hotel on Tuesday, September 10, 2024 at 9:00 a.m. ET
Webcasts of the fireside chat and presentation will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcasts will be available on the Company’s website for 90 days following the events.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHA Phase 1 heme trial). The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
When is TScan Therapeutics (TCRX) participating in the Morgan Stanley Global Healthcare Conference?
Where can I watch the webcasts of TScan Therapeutics' (TCRX) investor conference presentations?
What type of therapies is TScan Therapeutics (TCRX) developing?
How long will the archived replays of TScan Therapeutics' (TCRX) conference webcasts be available?
